NRX Pharmaceuticals, Inc. Paid-in-Kind Interest
NRX Pharmaceuticals, Inc. (NRXP) reported Paid-in-Kind Interest of $2.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2023-05-15
- NRX Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2022-03-31 was $2.00K, a 60.00% decline year-over-year.
- NRX Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2021-12-31 was $4.00K, a 86.58% decline year-over-year.
- NRX Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2021-09-30 was $5.00K, a 39.07% decline year-over-year.
- NRX Pharmaceuticals, Inc. paid-in-kind interest for the quarter ending 2021-06-30 was $5.00K.
- NRX Pharmaceuticals, Inc. paid-in-kind interest for fiscal 2021 was $19.00K, a 70.77% decline from fiscal 2020.
- NRX Pharmaceuticals, Inc. paid-in-kind interest for fiscal 2020 was $65.00K.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 6 month as first filed | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 9 month as first filed | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|---|---|
| 2022-03-31 | $2.00K 10-Q · filed 2023-05-15 | $6.00K derived: sum of 2 quarters · filed 2023-05-15 | $11.00K derived: sum of 3 quarters · filed 2023-05-15 | $16.00K derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $9.00K derived: sum of 2 quarters · filed 2023-03-31 | $14.00K derived: sum of 3 quarters · filed 2023-03-31 | $19.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.00K derived: sum of 2 quarters · filed 2022-11-14 | $15.00K 10-Q · filed 2022-11-14 | $15.65K 10-Q · filed 2021-11-15 | $44.80K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $10.00K 10-Q · filed 2022-08-15 | $10.29K 10-Q · filed 2021-08-16 | $39.80K derived: sum of 3 quarters · filed 2022-08-15 | $48.01K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $5.00K 10-Q · filed 2022-05-16 | $34.80K derived: sum of 2 quarters · filed 2022-05-16 | $43.01K derived: sum of 3 quarters · filed 2022-08-12 | |||
| 2020-12-31 | $29.80K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $38.01K derived: sum of 2 quarters · filed 2022-08-12 | $65.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $8.21K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-08-12 | $35.20K 10-Q/A · filed 2022-08-12 | ||||
| 2020-06-30 | $26.99K 10-Q/A · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |